publication date: Dec. 20, 2010

In this issue: 

FDA plans to discuss the negative trial of AstraZeneca’s drug Iressa with the Oncologic Drugs Advisory Committee in March.

Also in this 8-page issue: Safety warnings are added to labels for Epo and Avastin.

Cancer accounts for 23% of U.S. deaths, American Cancer Society says.

NCI sets its targets for grant success rate and R01 payline for FY05.

NIH panel calls for further research on end-of-life issues.

NAS committee urges greater rewards for interdisciplinary research.

CAM therapies should be held to conventional standards and Congress should toughen dietary supplements act, IOM panel says.

Funding opportunities listed.

Download (PDF 313KB)

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.